CelluTarget · Multifocal Motor Neuropathy · Treatments
✓ Standard of Care

Colchicine (low-dose, anti-inflammatory)

1
Evidence entries
0
Clinical trials
1
High-confidence findings
Overview
Treatment Details
Mechanism of Action
Anti-inflammatory agent that inhibits microtubule polymerization, impairing NLRP3 inflammasome assembly and IL-1β secretion — a key inflammatory pathway in atherosclerotic plaque progression. FDA-approved (Lodoco) for cardiovascular risk reduction in established CAD. Addresses "residual inflammatory risk" not covered by lipid-lowering therapy.
Dosing Notes
0.5 mg once daily (Lodoco formulation). Approved June 2023 for adults with established atherosclerotic disease or multiple cardiovascular risk factors.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
LoDoCo2 trial (2020): colchicine 0.5 mg/day in patients with chronic coronary disease reduced composite cardiovascular event rate by 31% vs placebo (HR 0.69, 95% CI 0.57–0.83). COLCOT trial (2019): colchicine after MI reduced risk of ischemic CV events by 23% vs placebo. FDA approved Lodoco for this indication in June 2023.
Verified Jul 2026
Peer Reviewed
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment (PMC 2026)
Published January 2026
View source ↗
Clinical Trials
Linked Trials
No clinical trials linked to this treatment yet.